CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.0% Today

What is CRISPR Therapeutics AG?

CRISPR Therapeutics (CRSP) is a gene-editing platform developer specializing in CRISPR/Cas9 therapies. The company's stock price closed at $52.75 USD on Nasdaq on May 14, 2026.

Why is CRISPR Therapeutics AG going down?

CRSP stock is down 5.0% on May 14, 2026 16:45

• The bearish movement in CRISPR Therapeutics' stock today can be attributed to a wider-than-expected loss in Q1 2026, coupled with sales missing analyst estimates. This disappointing financial performance likely led to a decrease in investor confidence.
• Despite a top Wall Street analyst's bullish outlook and a raised price target by Bernstein, the concerns surrounding the company's financial results may have overshadowed the positive sentiments.
• The recent reduction in stock position by Vanguard Group Inc. and the dilution concerns raised by the company's new capital raise through convertible notes could have added selling pressure on the stock.
• While CRISPR Therapeutics' innovative gene-editing platform and promising pipeline offer long-term growth potential, the current challenges in financial performance and investor uncertainty regarding its future may have driven the bearish market movement today.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

CRISPR Therapeutics stock (CH0334081137): Bernstein raises price target amid gene-editing momentum

Bernstein has raised its price target for CRISPR Therapeutics (CH0334081137) to $56, maintaining its rating and reflecting confidence in the gene-editing platform developer's therapeutic pipeline. CRISPR Therapeutics, specializing in CRISPR/Cas9 gene-editing therapies, is watched by investors for its potential in precision medicine, with its financial trajectory dependent on advancing candidates through regulatory approval and commercialization. The company's stock traded at $52.75 USD on May 14, 2026, on Nasdaq.

https://www.ad-hoc-news.de/boerse/news/ueberblick/crispr-therapeutics-stock-ch0334081137-bernstein-raises-price-target/69334382

Vanguard Group Inc. Reduces Stock Position in CRISPR Therapeutics AG $CRSP

Vanguard Group Inc. decreased its stake in CRISPR Therapeutics AG by 4.1% in the fourth quarter, selling 96,251 shares and retaining 2.27 million shares valued at approximately $119 million. Despite this, institutional investors collectively own 69.2% of the company's stock, with several hedge funds increasing their positions. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $66.06, although company insiders have been net sellers in the last 90 days.

https://www.marketbeat.com/instant-alerts/filing-vanguard-group-inc-reduces-stock-position-in-crispr-therapeutics-ag-crsp-2026-05-13/

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

A top Wall Street analyst believes CRISPR Therapeutics (CRSP) could more than double, with Piper Sandler's Edward Tenthoff setting a $110 price target. This bullish sentiment is fueled by potential catalysts like upcoming clinical trial data readouts for candidates such as the anticoagulant CTX611 and potential expansion of its approved product, Casgevy, to younger patients. While the stock carries risk due to its volatility and reliance on clinical success, its innovative gene-editing platform and robust pipeline, backed by $2.4 billion in cash, suggest promising long-term growth for investors with a high risk tolerance.

https://www.fool.com/investing/2026/05/11/1-top-wall-street-analyst-thinks-crispr-therapeuti/

The Bull Case For CRISPR Therapeutics (CRSP) Could Change Following CASGEVY Uptake And New Capital Raise – Learn Why

CRISPR Therapeutics recently reported Q1 2026 results, showing continued commercial uptake of CASGEVY and progress in its gene editing pipeline. The company also secured $600 million in convertible notes, bolstering its balance sheet but raising dilution concerns. While CASGEVY's success and pipeline advancements are crucial, a wide range of fair value estimates highlights investor uncertainty regarding the company's long-term potential and current cash burn.

https://www.sahmcapital.com/news/content/the-bull-case-for-crispr-therapeutics-crsp-could-change-following-casgevy-uptake-and-new-capital-raise-learn-why-2026-05-09

CRISPR Therapeutics' Q1 loss wider than expected, sales miss estimates

CRISPR Therapeutics (CRSP) reported a wider-than-expected loss in Q1 2026, with sales also missing analyst estimates. The biotechnology company posted a loss of $1.90 per share against an estimated loss of $1.76 per share, and revenue of $0.20 million, significantly below the expected $4.18 million. This financial performance indicates challenges for the gene-editing company in the reported quarter despite its innovative research.

https://www.msn.com/en-us/money/topstocks/crispr-therapeutics-q1-loss-wider-than-expected-sales-miss-estimates/ar-AA22r86Y?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Trending Today

FMC Corporation ($FMC) Stock Forecast: Up 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Down 5.0% Today

Chegg Inc. ($CHGG) Stock Forecast: Down 5.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 10.7% Today

Cisco Systems Inc. ($CSCO) Stock Forecast: Up 15.0% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.0% Today

Groupon Inc. ($GRPN) Stock Forecast: Down 5.6% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Up 6.4% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 18.8% Today

CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.0% Today

CRISPR Therapeutics AG Price History

07.03.2026 - CRSP Stock was down 5.1%

• Despite recent developments on the company's gene-editing therapy, Casgevy, leading to revenue generation and a strong financial position, the stock faced a bearish trend.
• The stock's downturn might be attributed to temporary market fluctuations or profit-taking following a substantial rise in its value in the past year.
• Analysts' varied viewpoints, with Mizuho Securities reconfirming a Buy rating and Piper Sandler also recommending a Buy, could have contributed to the stock's volatility.
• Investors are likely exercising caution ahead of the upcoming earnings release and closely tracking any alterations in forecasts, potentially impacting the stock's short-term performance.

14.04.2026 - CRSP Stock was down 5.0%

• The bearish movement in CRISPR Therapeutics' stock today can be attributed to a wider-than-expected loss in Q1 2026, coupled with sales missing analyst estimates. This disappointing financial performance likely led to a decrease in investor confidence.
• Despite a top Wall Street analyst's bullish outlook and a raised price target by Bernstein, the concerns surrounding the company's financial results may have overshadowed the positive sentiments.
• The recent reduction in stock position by Vanguard Group Inc. and the dilution concerns raised by the company's new capital raise through convertible notes could have added selling pressure on the stock.
• While CRISPR Therapeutics' innovative gene-editing platform and promising pipeline offer long-term growth potential, the current challenges in financial performance and investor uncertainty regarding its future may have driven the bearish market movement today.

08.04.2026 - CRSP Stock was up 5.2%

• Despite a wider loss than anticipated and revenue results falling short in the initial quarter, CRISPR Therapeutics AG (CRSP) shares rose by 3.8% during midday trading, indicating positive market sentiment.
• Investor interest seems to be more focused on the company's advancements in product approvals, pipeline expansion, and strategic collaborations rather than solely on financial performance.
• The stock's upward movement may also be influenced by analysts upholding a "Moderate Buy" rating for CRSP shares, with an average price target of $64.53, underscoring faith in the company's long-term growth trajectory.
• The conflicting financial results suggest that while revenue challenges exist, the market holds an optimistic view on CRISPR Therapeutics AG's future prospects in the gene therapy sector.

08.03.2026 - CRSP Stock was up 5.8%

• The recent upward trend in CRISPR Therapeutics' stock price is believed to be linked to the announcement of its senior management team partaking in the 25th Annual Needham Virtual Healthcare Conference. This participation likely boosted investor confidence in the company's future.
• Market enthusiasm towards CRSP is also bolstered by the commercial revenue from its gene-editing therapy, Casgevy, developed in collaboration with Vertex Pharmaceuticals. This revenue stream and the company's strong financial position for upcoming trials indicate potential growth and stability.
• Analysts' assessments, including a Zacks Rank of #3 (Hold), reveal a cautiously optimistic outlook towards CRISPR Therapeutics' performance, with anticipated substantial revenue growth. This positive sentiment could have contributed to the stock's recent bullish movement.

24.03.2026 - CRSP Stock was down 5.6%

• CRISPR Therapeutics AG (CRSP) stock dropped significantly, underperforming the broader market and closing at $63.09.
• The underperformance could be attributed to the company's recent Q4 earnings miss and revenue decline, leading to net selling by company insiders.
• Investors may be cautious due to the company's upcoming annual general meeting, where proposals include carrying forward a significant accumulated net loss and approving compensation for the Board and Executive Committee.
• Despite the bearish movement, the positive long-term outlook for CRISPR Therapeutics, with advancements in gene-based medicines and promising pipeline assets, suggests potential for future growth and recovery in stock performance.

24.03.2026 - CRSP Stock was down 5.7%

• The stock price of CRISPR Therapeutics (CRSP) dropped by 1.48% during the trading session, closing at $65.80, underperforming the broader market indices like the S&P 500.
• Analysts suggest that the stock may be undervalued based on a Discounted Cash Flow (DCF) model, projecting an intrinsic value significantly higher than the current price.
• Investors are eagerly awaiting positive movement in upcoming earnings reports to potentially reverse the trend of underperformance compared to its peers.
• Despite the company's strategic advancements in gene-based medicines and a positive long-term outlook for its gene-editing portfolio, the stock's movement today reflects market concerns and the need for tangible financial results to drive investor confidence.

13.03.2026 - CRSP Stock was up 5.0%

• CRISPR Therapeutics (CRSP) experienced a strong bullish movement today, likely driven by a combination of factors:
• The company's expansion of its gene-editing pipeline with programs focusing on cardiovascular and metabolic conditions, such as CTX310 and CTX320, has generated positive investor sentiment.
• The forecasted rapid growth of the biomedical CRISPR gene editing market, in which CRISPR Therapeutics is a key player, has likely contributed to the bullish trend.
• Despite facing challenges like significant losses and cash burn, the company's strategic positioning in the gene-editing sector and its participation in high-profile events have boosted investor confidence.
• Analyst valuations and pricing metrics indicating potential undervaluation of CRSP stock have also likely attracted investors seeking growth opportunities in the biotech industry.

14.03.2026 - CRSP Stock was up 5.3%

• Positive investor sentiment and optimism have driven a bullish movement in CRSP's stock today, fueled by recent developments and future prospects.
• The successful launch of Casgevy, generating over $100 million in sales, along with plans to expand the pipeline with six upcoming data readouts in the next 6-12 months, have boosted investor confidence.
• Despite a larger-than-expected quarterly loss, CRISPR Therapeutics' improved cash position, substantial cash reserves of nearly $2 billion, and promising pipeline developments targeting cardiovascular diseases and cancers have attracted investor interest.
• CRISPR's focus on one-time gene edits for conditions related to lipids and metabolic programs like CTX310 and CTX320 presents a compelling long-term investment opportunity, despite challenges such as significant losses and ongoing cash burn, with high execution risk.

17.03.2026 - CRSP Stock was up 5.7%

• Despite recent financial results falling short of expectations, including a larger-than-anticipated quarterly loss and a decline in revenue, CRISPR Therapeutics is capitalizing on the sales growth of its approved therapy, Casgevy, to venture into new areas such as cardiovascular disease, cancers, and autoimmune disorders.
• Analysts are optimistic about the company's potential for future growth, foreseeing substantial revenue growth and major pipeline expansions, including the anticipation of six data readouts in the next 6-12 months.
• The stock's upward trend could be attributed to the excitement surrounding the upcoming clinical program readouts and CRISPR Therapeutics' strategic positioning at the intersection of scientific advancement and commercial strategy, despite some insider selling and mixed analyst outlooks.
• The market's positive reaction to the company's growth strategies and the success of Casgevy in driving sales and establishing treatment centers likely influenced the stock's bullish performance for the day.

06.04.2026 - CRSP Stock was up 5.8%

• CRSP stock demonstrated a 3.8% increase in midday trading, suggesting that investors could be focusing on favorable aspects of the company's performance despite the reported loss and revenue shortfall.
• The company's advancements in product approvals, pipeline development, and strategic partnerships highlighted in the financial update might have boosted investor confidence, leading to the positive market movement.
• The financial results, including a narrower loss per share than expected and revenue below projections, potentially instilled optimism that the company is effectively managing expenses and progressing strategically amid revenue challenges.
• Although insider stock sales and convertible notes offerings were noted, the overall market sentiment appears to have been influenced by the positive outlook presented in the company's financial update and future growth opportunities.

05.04.2026 - CRSP Stock was down 5.1%

• CRSP stock experienced a bearish movement today despite reporting its first-quarter 2026 financial results.
• The earnings miss, with an adjusted EPS of -$1.28 and revenue of $1.46 million falling short of expectations, likely contributed to the negative market reaction.
• Despite ongoing progress in product approvals and pipeline development, the significant revenue miss compared to estimates may have raised concerns among investors about the company's financial performance.
• The discrepancy between the reported financials and the estimated fair value of the stock, indicating a potential undervaluation, could also be a factor in the bearish market movement as investors reassess the company's growth prospects and risks.

12.04.2026 - CRSP Stock was down 5.8%

• An optimistic outlook from a top Wall Street analyst suggesting a potential doubling of CRISPR Therapeutics' stock price is contrasted by a wider-than-expected loss in Q1 2026 and missed sales estimates, influencing a bearish market response.
• Despite the positive commercial uptake of CASGEVY and advancements in the gene editing pipeline, concerns about dilution from a recent capital raise and uncertainty about the company's future potential have likely contributed to the stock's decline.
• The decrease in Nwam LLC's holdings, despite positive analyst ratings, reflects a cautious stance towards CRISPR Therapeutics, particularly given its high-risk pre-profitability stage and recent quarterly losses.
• Data on the number of shareholders, while not indicative of market sentiment, underscores the ongoing interest and activity surrounding CRISPR Therapeutics' stock.